Shortly after the publication of TREAT, the Anemia Working Group of the ERBP recommended targeting Hb levels of 11–12 g/dL in CKD patients, and to not intentionally exceed 13 g/dL (Locatelli et al., 2010). Here, GSTM1 is linked to anemia (phenotype).